BerGenBio ASA

BerGenBio ASA
About Us
Change country

Follow us:
Share:
Subscribe:

About Us

BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate, bemcentinib, a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and severe respiratory infections.

BerGenBio: Updated phII clinical data with selective AXL inhibitor bemcentinib strengthens its potential to improve NSCLC patient outcomes

Tue, Sep 25, 2018 16:00 CET

· Overall response rate of 40% with the bemcentinib/KEYTRUDA combination observed in AXL-positive, previously treated NSCLC patients, including PD-L1 negative patients who are not expected to benefit from KEYTRUDA monotherapy · Median PFS of patients receiving the bemcentinib/TARCEVA combination in first line has surpassed that of TARCEVA monotherapy · Encouraging efficacy reported for bemcentinib in combination with docetaxel chemotherapy in patients who had exhausted all available therapy options including anti-PD-(L)1 · Phase II trial design revealed combining bemcentinib and

BerGenBio ASA: Results for the First Quarter 2018

Tue, May 15, 2018 07:00 CET

Bergen, Norway, 15 May 2018 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, announces its results for the first quarter 2018. A presentation of the results by the Company’s management will take place today at 10.00 am CET in Oslo – details below.Richard Godfrey, Chief Executive Officer of BerGenBio, commented: “We are pleased with the progress made during Q1 2018. Patient recruitment into our global Phase II clinical proof-of-concept trials with bemcentinib is progressing well and we

BerGenBio participation at upcoming healthcare investor and life sciences industry conferences

Mon, May 14, 2018 12:30 CET

Bergen, Norway, 14 May 2018– BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, will be participating at the following upcoming conferences.· 14-16 May, Bio€quity Europe 2018 (Ghent, Belgium)* · 23 May, ABG Sundal Collier Cancer Seminar (Stockholm, Sweden)* · 1 June, Sachs Immuno-Oncology BD&L and Investment Forum (Chicago, IL)* · 4 June, Norne Securities Conference (Bergen, Norway)* · 1-5 June, 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO) (Chicago,

BerGenBio meets first efficacy endpoint in phase II trial with selective AXL inhibitor BGB324 (bemcentinib) in NSCLC

Tue, Jan 09, 2018 08:00 CET

Trial aims to evaluate the effectiveness of BGB324 (bemcentinib) in preventing and reversing resistance to targeted therapyBergen, Norway, January 9, 2018 – BerGenBio ASA (OSE:BGBIO) , a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors as a potential cornerstone of combination cancer therapy, announces that the first efficacy endpoint has been met in its phase II clinical trial evaluating BGB324 (bemcentinib), a selective AXL inhibitor, in combination with erlotinib in patients with advanced non-small cell lung cancer (

BGB324, BerGenBio's Selective First-in-Class AXL Inhibitor, Featured in 3 Clinical Presentations at 18th World Conference on Lung Cancer in Yokohama

Mon, Oct 16, 2017 08:00 CET

Bergen, Norway, October 16, 2017 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors for multiple cancer indications, announces presentations on three ongoing Phase 2 clinical trials with BGB324 in lung cancer patients at the 18th World Conference on Lung Cancer in Yokohama, Japan.BGB324, a first-in-class selective Axl inhibitor, is being investigated in three Phase 2 clinical trials across the three standard-of-care treatment regimens available to patients with non-small-cell lung cancer (NSCLC): these trials seek to

BGB324, BerGenBio's Selective First-in-Class AXL Inhibitor, Featured in Three Clinical Presentations at the 18th World Conference on Lung Cancer

Thu, Sep 28, 2017 08:00 CET

Bergen, Norway, Sep 28 2017 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors for multiple cancer indications, is pleased to announce that the Company will present three ongoing lung cancer clinical trials with BGB324 at the 18th World Conference on Lung Cancer in Yokohama, Japan, October 15 – 18, 2017.The three presentations will show clinical results to date and discuss the rationale of the clinical studies undertaken with BGB324, BerGenBio’s lead candidate, a first-in-class and highly

There are no items matching the current filter

There are no more items matching the current filter

Share